Tuberculosis-associated IFN-I induces Siglec-1 on tunneling nanotubes and favors HIV-1 spread in macrophages

  1. Maeva Dupont
  2. Shanti Souriant
  3. Luciana Balboa
  4. Thien-Phong Vu Manh
  5. Karine Pingris
  6. Stella Rousset
  7. Céline Cougoule
  8. Yoann Rombouts
  9. Renaud Poincloux
  10. Myriam Ben Neji
  11. Carolina Allers
  12. Deepak Kaushal
  13. Marcelo J Kuroda
  14. Susana Benet
  15. Javier Martinez-Picado
  16. Nuria Izquierdo-Useros
  17. Maria del Carmen Sasiain
  18. Isabelle Maridonneau-Parini
  19. Olivier Neyrolles
  20. Christel Vérollet  Is a corresponding author
  21. Geanncarlo Lugo-Villarino  Is a corresponding author
  1. Institute de Pharmacologie et de Biologie Structurale (IPBS), France
  2. Academia Nacional de Medicina/Conicet, Argentina
  3. Aix Marseille University, France
  4. Tulane National Primate Research Center, United States
  5. Tulane University School of Medicine, United States
  6. University of California, Davis, United States
  7. IrsiCaixa AIDS Research Institute, Spain
  8. Universitat Autònoma de Barcelona, Spain
  9. AIDS Research Institute IrsiCaixa, Spain
  10. Université de Toulouse, CNRS, France

Abstract

While tuberculosis (TB) is a risk factor in HIV-1-infected individuals, the mechanisms by which Mycobacterium tuberculosis (Mtb) worsens HIV-1 pathogenesis remain scarce. We showed that HIV-1 infection is exacerbated in macrophages exposed to TB-associated microenvironments due to tunneling nanotube (TNT) formation. To identify molecular factors associated with TNT function, we performed a transcriptomic analysis in these macrophages, and revealed the up-regulation of Siglec-1 receptor. Siglec-1 expression depends on Mtb-induced production of type I interferon (IFN-I). In co-infected non-human primates, Siglec-1 is highly expressed by alveolar macrophages, whose abundance correlates with pathology and activation of IFN-I/STAT1 pathway. Siglec-1 localizes mainly on microtubule-containing TNT that are long and carry HIV-1 cargo. Siglec-1 depletion decreases TNT length, diminishes HIV-1 capture and cell-to-cell transfer, and abrogates the exacerbation of HIV-1 infection induced by Mtb. Altogether, we uncover a deleterious role for Siglec-1 in TB-HIV-1 co-infection and opens new avenues to understand TNT biology.

Data availability

The raw data for the transcriptome analysis in this manuscript was made available through the public by a deposit to GEO under the accession code GSE139511.

The following data sets were generated

Article and author information

Author details

  1. Maeva Dupont

    Tuberculosis and Infection Biology (TBIB), Institute de Pharmacologie et de Biologie Structurale (IPBS), Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  2. Shanti Souriant

    Tuberculosis and Infection Biology (TBIB), Institute de Pharmacologie et de Biologie Structurale (IPBS), Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  3. Luciana Balboa

    IMEX, Academia Nacional de Medicina/Conicet, Buenos Aires, Argentina
    Competing interests
    The authors declare that no competing interests exist.
  4. Thien-Phong Vu Manh

    CIML, Aix Marseille University, Marseille, France
    Competing interests
    The authors declare that no competing interests exist.
  5. Karine Pingris

    Tuberculosis and Infection Biology (TBIB), Institute de Pharmacologie et de Biologie Structurale (IPBS), Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  6. Stella Rousset

    Tuberculosis and Infection Biology (TBIB), Institute de Pharmacologie et de Biologie Structurale (IPBS), Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  7. Céline Cougoule

    Tuberculosis and Infection Biology (TBIB), Institute de Pharmacologie et de Biologie Structurale (IPBS), Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  8. Yoann Rombouts

    Tuberculosis and Infection Biology (TBIB), Institute de Pharmacologie et de Biologie Structurale (IPBS), Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  9. Renaud Poincloux

    Tuberculosis and Infection Biology (TBIB), Institute de Pharmacologie et de Biologie Structurale (IPBS), Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  10. Myriam Ben Neji

    Tuberculosis and Infection Biology (TBIB), Institute de Pharmacologie et de Biologie Structurale (IPBS), Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  11. Carolina Allers

    Microbiology and Immunology, Tulane National Primate Research Center, New Orleans, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Deepak Kaushal

    Tulane National Primate Research Center, Tulane University School of Medicine, Covington, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. Marcelo J Kuroda

    Center for Comparative Medicine and California National Primate Research Center, University of California, Davis, Davis, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. Susana Benet

    Retrovirology, IrsiCaixa AIDS Research Institute, Badalona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  15. Javier Martinez-Picado

    AIDS Research Institute IrsiCaixa, Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  16. Nuria Izquierdo-Useros

    Retrovirology, AIDS Research Institute IrsiCaixa, Badalona, Spain
    Competing interests
    The authors declare that no competing interests exist.
  17. Maria del Carmen Sasiain

    IMEX, Academia Nacional de Medicina/Conicet, Buenos Aires, Argentina
    Competing interests
    The authors declare that no competing interests exist.
  18. Isabelle Maridonneau-Parini

    Tuberculosis and Infection Biology (TBIB), Institute de Pharmacologie et de Biologie Structurale (IPBS), Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  19. Olivier Neyrolles

    Université de Toulouse, CNRS, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  20. Christel Vérollet

    Tuberculosis and Infection Biology (TBIB), Institute de Pharmacologie et de Biologie Structurale (IPBS), Toulouse, France
    For correspondence
    verollet@ipbs.fr
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1079-9085
  21. Geanncarlo Lugo-Villarino

    Tuberculosis and Infection Biology (TBIB), Institute de Pharmacologie et de Biologie Structurale (IPBS), Toulouse, France
    For correspondence
    geanncarlo.lugo@ipbs.fr
    Competing interests
    The authors declare that no competing interests exist.

Funding

Agence Nationale de la Recherche (ANRS2014-049)

  • Olivier Neyrolles

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: Non‑Human Primate (NHP) samplesAll animal procedures were approved by the Institutional Animal Care and Use Committee of Tulane University, New Orleans, LA and were performed at the Tulane TNPRC, and under approval from IACUC (project numbers P3733, P3794, P3373 and P3628). They were performed in strict accordance with NIH guidelines.

Human subjects: Human SubjectsMonocytes from healthy subjects were provided by Etablissement Français du Sang (EFS), Toulouse, France, under contract 21/PLER/TOU/IPBS01/20130042. According to articles L12434 and R124361 of the French Public Health Code, the contract was approved by the French Ministry of Science and Technology (agreement number AC 2009921). Written informed consents were obtained from the donors before sample collection.

Copyright

© 2020, Dupont et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,866
    views
  • 475
    downloads
  • 40
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Maeva Dupont
  2. Shanti Souriant
  3. Luciana Balboa
  4. Thien-Phong Vu Manh
  5. Karine Pingris
  6. Stella Rousset
  7. Céline Cougoule
  8. Yoann Rombouts
  9. Renaud Poincloux
  10. Myriam Ben Neji
  11. Carolina Allers
  12. Deepak Kaushal
  13. Marcelo J Kuroda
  14. Susana Benet
  15. Javier Martinez-Picado
  16. Nuria Izquierdo-Useros
  17. Maria del Carmen Sasiain
  18. Isabelle Maridonneau-Parini
  19. Olivier Neyrolles
  20. Christel Vérollet
  21. Geanncarlo Lugo-Villarino
(2020)
Tuberculosis-associated IFN-I induces Siglec-1 on tunneling nanotubes and favors HIV-1 spread in macrophages
eLife 9:e52535.
https://doi.org/10.7554/eLife.52535

Share this article

https://doi.org/10.7554/eLife.52535

Further reading

    1. Cell Biology
    2. Genetics and Genomics
    Keva Li, Nicholas Tolman ... UK Biobank Eye and Vision Consortium
    Research Article

    A glaucoma polygenic risk score (PRS) can effectively identify disease risk, but some individuals with high PRS do not develop glaucoma. Factors contributing to this resilience remain unclear. Using 4,658 glaucoma cases and 113,040 controls in a cross-sectional study of the UK Biobank, we investigated whether plasma metabolites enhanced glaucoma prediction and if a metabolomic signature of resilience in high-genetic-risk individuals existed. Logistic regression models incorporating 168 NMR-based metabolites into PRS-based glaucoma assessments were developed, with multiple comparison corrections applied. While metabolites weakly predicted glaucoma (Area Under the Curve = 0.579), they offered marginal prediction improvement in PRS-only-based models (p=0.004). We identified a metabolomic signature associated with resilience in the top glaucoma PRS decile, with elevated glycolysis-related metabolites—lactate (p=8.8E-12), pyruvate (p=1.9E-10), and citrate (p=0.02)—linked to reduced glaucoma prevalence. These metabolites combined significantly modified the PRS-glaucoma relationship (Pinteraction = 0.011). Higher total resilience metabolite levels within the highest PRS quartile corresponded to lower glaucoma prevalence (Odds Ratiohighest vs. lowest total resilience metabolite quartile=0.71, 95% Confidence Interval = 0.64–0.80). As pyruvate is a foundational metabolite linking glycolysis to tricarboxylic acid cycle metabolism and ATP generation, we pursued experimental validation for this putative resilience biomarker in a human-relevant Mus musculus glaucoma model. Dietary pyruvate mitigated elevated intraocular pressure (p=0.002) and optic nerve damage (p<0.0003) in Lmx1bV265D mice. These findings highlight the protective role of pyruvate-related metabolism against glaucoma and suggest potential avenues for therapeutic intervention.

    1. Cell Biology
    Affiong Ika Oqua, Kin Chao ... Alejandra Tomas
    Research Article

    G protein-coupled receptors (GPCRs) are integral membrane proteins which closely interact with their plasma membrane lipid microenvironment. Cholesterol is a lipid enriched at the plasma membrane with pivotal roles in the control of membrane fluidity and maintenance of membrane microarchitecture, directly impacting on GPCR stability, dynamics, and function. Cholesterol extraction from pancreatic beta cells has previously been shown to disrupt the internalisation, clustering, and cAMP responses of the glucagon-like peptide-1 receptor (GLP-1R), a class B1 GPCR with key roles in the control of blood glucose levels via the potentiation of insulin secretion in beta cells and weight reduction via the modulation of brain appetite control centres. Here, we unveil the detrimental effect of a high cholesterol diet on GLP-1R-dependent glucoregulation in vivo, and the improvement in GLP-1R function that a reduction in cholesterol synthesis using simvastatin exerts in pancreatic islets. We next identify and map sites of cholesterol high occupancy and residence time on active vs inactive GLP-1Rs using coarse-grained molecular dynamics (cgMD) simulations, followed by a screen of key residues selected from these sites and detailed analyses of the effects of mutating one of these, Val229, to alanine on GLP-1R-cholesterol interactions, plasma membrane behaviours, clustering, trafficking and signalling in INS-1 832/3 rat pancreatic beta cells and primary mouse islets, unveiling an improved insulin secretion profile for the V229A mutant receptor. This study (1) highlights the role of cholesterol in regulating GLP-1R responses in vivo; (2) provides a detailed map of GLP-1R - cholesterol binding sites in model membranes; (3) validates their functional relevance in beta cells; and (4) highlights their potential as locations for the rational design of novel allosteric modulators with the capacity to fine-tune GLP-1R responses.